ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
Tavaborole Topical Solution, 5% had annual sales of US $3.1 million in the United States
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Azithromycin Tablets USP, 500 mg had annual sales of US $20 million in the United States
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
Urges everyone to follow COVID Appropriate Behaviour and curb any misinformation
To enable company to be future-ready by tapping potential in CDMO space
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Subscribe To Our Newsletter & Stay Updated
